Latest news with #DavidDardashti
Associated Press
22-05-2025
- Health
- Associated Press
Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
DENVER, CO - May 21, 2025 - Ibogaine By David Dardashti, will be hosting a booth at the upcoming Psychedelic Science 2025 conference, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The conference, a premier global gathering for psychedelic research, medicine, policy, and culture, will take place from June 16-20, 2025, at the Colorado Convention Center. Ibogaine By David Dardashti is expected to share profound insights into specific ibogaine treatment protocols tailored to diverse needs, a hallmark of his approach. This information will delve into the nuanced application of ibogaine for a range of conditions, including: Attendees will gain a precise understanding of the ramifications of these specific treatment lengths in relation to an individual's unique needs and circumstances. Dardashti will also illuminate the overall ibogaine experience, explaining its mechanisms and transformative potential with clarity and precision, particularly concerning its application beyond addiction to other challenging health conditions. Known for his work at Ibogaine by David Dardashti, he has long advocated for individualized care, emphasizing the importance of addressing the root causes of various ailments. His presence at Psychedelic Science 2025 offers a significant opportunity for clinicians, researchers, and the wider psychedelic community to learn about these structured and potentially pioneering approaches to ibogaine therapy. About David Dardashti: David Dardashti is a leading expert in ibogaine treatment with extensive experience in developing personalized protocols for addiction, psychological well-being, and other complex health conditions. About Psychedelic Science 2025: Psychedelic Science 2025, hosted by MAPS, is the leading international conference dedicated to the study of psychedelic substances for science, medicine, spirituality, and policy. It brings together experts from around the world to share the latest research and developments in the field. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
Associated Press
08-05-2025
- Health
- Associated Press
Ibogaine By David Dardashti to Present Innovative Childhood Trauma Healing Approach at 2025 Psychedelic Conference
Miami, Florida - May 7, 2025 - Ibogaine By David Dardashti today announced they will be sharing their pioneering work on healing childhood trauma at a major psychedelic conference in 2025. Their unique approach combines the therapeutic power of ibogaine with professional therapy and insights gained from patient experiences, specifically targeting the 'Inner Child.' Childhood trauma can leave deep, lasting wounds, contributing to issues like PTSD, anxiety, and depression. This often affects the 'Inner Child' – that core part of us holding innocence and vulnerability. When this part is hurt, it impacts our well-being into adulthood. Ibogaine, a natural substance, is known for creating a profound internal journey. This introspective experience allows individuals to revisit and process past memories and emotions in a new light, crucial for acknowledging and beginning to heal the wounded Inner Child. David Dardashti will explain how this deep dive helps 'unravel' this affected part of the self. To support this powerful process, Ibogaine By David Dardashti integrates dedicated clinical psychology. Therapists provide essential guidance before, during, and after the ibogaine session, helping patients understand their experience and integrate insights into their lives for lasting change. A key part of this work involves learning from patients. By analyzing experiences and conditions, the team develops deeper insights into how trauma affects the Inner Child, helping improve treatment strategies. Patient testimonials also provide valuable understanding into the healing journey. These findings will be presented at a leading psychedelic conference in 2025, highlighting how combining ibogaine's unique effects with expert care and patient data offers new hope for those seeking to heal deep-seated trauma. 'We believe that healing the wounded 'Inner Child' is key to recovering from childhood trauma,' says David Dardashti. 'By bringing together the insightful journey of ibogaine, expert therapy, and learning from each patient, we are finding powerful ways to help people heal. We look forward to sharing this work at the 2025 conference.' This innovative approach offers a path to lasting healing by addressing the core impacts of childhood trauma. Presentation Details: Ibogaine By David Dardashti will present their findings at Pscychadelic Confrence 2025 in Denver Colorado. Specific presentation details will be announced closer to the event. About Ibogaine By David Dardashti: Ibogaine By David Dardashti is a center providing safe, medically supervised ibogaine therapy for addiction and trauma, combining medical care with psychological support for comprehensive healing. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine By David Dardashti to Present Innovative Childhood Trauma Healing Approach at 2025 Psychedelic Conference
Globe and Mail
28-02-2025
- Health
- Globe and Mail
Ibogaine by David Dardashti Redefines Addiction Treatment with Therapeutic Adventures in Mexico
Ibogaine by David Dardashti, a leading provider of ibogaine treatment for addiction, today announced a groundbreaking initiative that combines cutting-edge therapy with transformative travel experiences. The company is now offering clients the opportunity to participate in fully-funded therapeutic adventures to breathtaking destinations in Mexico, including Isla Mujeres, Cozumel, Tulum, and ancient Mayan ruins. This innovative approach recognizes the importance of integrating healing with enriching experiences. By immersing clients in the natural beauty and cultural richness of Mexico, Ibogaine by David Dardashti aims to enhance the therapeutic benefits of ibogaine treatment and foster a deeper connection to self and the world. "We believe that true healing goes beyond the clinical setting," says David Dardashti, founder of Ibogaine by David Dardashti. "By incorporating therapeutic adventures into our treatment program, we are providing our clients with a unique opportunity to reflect, recharge, and reconnect with their inner strength in breathtaking environments." These carefully curated excursions are led by expert guides who facilitate reflection and introspection, helping clients process their experiences and solidify the gains made during ibogaine treatment. The adventures are designed to complement the therapeutic process, promoting a sense of renewal, wonder, and lasting recovery. Destinations Include: Isla Mujeres: Escape to this idyllic island paradise, renowned for its pristine beaches, crystal-clear turquoise waters, and laid-back atmosphere. Swim with gentle whale sharks, explore the vibrant coral reefs, and discover the island's rich cultural heritage. Cozumel: Immerse yourself in the underwater wonders of Cozumel, a world-renowned diving destination. Explore the Palancar Reef, a vibrant ecosystem teeming with marine life. Discover hidden cenotes, natural sinkholes filled with crystal-clear water, and experience the island's unique blend of Mayan and Mexican culture. Tulum: Journey to the ancient Mayan walled city of Tulum, perched dramatically on cliffs overlooking the turquoise Caribbean Sea. Explore the well-preserved ruins, learn about Mayan history and cosmology, and soak in the breathtaking natural beauty of the Riviera Maya. Mayan Ruins: Delve deeper into the fascinating world of the ancient Mayans with visits to iconic archaeological sites like Chichen Itza and Uxmal. Marvel at the towering pyramids, intricate carvings, and astronomical observatories, gaining a deeper understanding of this ancient civilization's profound connection to nature and the cosmos. Ibogaine by David Dardashti is committed to providing safe, effective, and compassionate ibogaine treatment for addiction. With this new initiative, the company is setting a new standard for holistic addiction recovery, combining the power of ibogaine with the transformative potential of travel.
Globe and Mail
21-02-2025
- Health
- Globe and Mail
Ibogaine by David Dardashti Explores Groundbreaking Research Linking Genetic Enhancers to Neurological Disease Treatment, Including Parkinson's
Ibogaine by David Dardashti, a leading voice in the exploration of ibogaine's therapeutic potential, is closely analyzing a new study published in EMBO Reports that sheds light on the intricate genetic mechanisms underlying neurological disorders, including Parkinson's disease. This research, spearheaded by Associate Professor Masahito Yoshihara and colleagues, provides compelling evidence that could significantly impact the understanding and application of ibogaine treatment. The study utilized advanced genomic techniques, including CAGE, NET-CAGE, and Capture Hi-C/HiCap, to identify and characterize thousands of enhancers – non-coding DNA regions that play a crucial role in gene regulation – active during neuronal differentiation. Crucially, the researchers discovered a significant enrichment of genetic variants (SNPs) associated with Parkinson's disease and schizophrenia within these enhancers. This finding suggests that these enhancers, and the genes they regulate, are directly implicated in the development and progression of these conditions. David Dardashti, a prominent advocate for ibogaine research, recognizes the profound implications of this study for the field of ibogaine therapy. "This research provides a critical piece of the puzzle in understanding how ibogaine may exert its remarkable effects," Dardashti explains. "By demonstrating the direct involvement of specific genetic enhancers in neurological disorders, it opens up exciting new avenues for exploring ibogaine's mechanism of action at a molecular level." Ibogaine has shown promise in anecdotal reports and preliminary studies for its ability to alleviate symptoms of neurological conditions, including addiction, and potentially Parkinson's. Its purported anti-aging and restorative properties have also garnered significant interest. While the exact mechanisms remain under investigation, one hypothesis centers on ibogaine's potential to influence gene expression, possibly through interactions with these very enhancers identified in the EMBO Reports study. The study's focus on LUHMES cells, a model for human dopaminergic neurons (the cells primarily affected in Parkinson's disease), is particularly relevant. By linking specific enhancers to genes involved in neuronal differentiation and disorders, the research provides a potential roadmap for understanding how ibogaine might influence these crucial cellular processes. Dardashti is particularly intrigued by the potential connection between the identified genetic enhancers and the "genetic rejuvenating factors" hypothesized to be influenced by ibogaine. "If ibogaine can modulate the activity of these enhancers, which are clearly linked to neurological health and disease, it could explain its reported ability to promote neuroplasticity, reduce neuroinflammation, and potentially even reverse some of the cellular damage associated with conditions like Parkinson's," he notes. The research highlights the "vast regulatory potential embedded in non-coding regions" of the genome. This aligns with the emerging understanding of ibogaine's potential to induce broad-spectrum changes in gene expression, leading to long-lasting therapeutic effects. Ibogaine by David Dardashti is committed to rigorously examining the findings of this and other related studies. This deeper dive will help determine, specifically the implications for ibogaine treatment protocols and future research directions. The goal is to move beyond anecdotal evidence and establish a solid scientific foundation for ibogaine's use in treating neurological disorders, including the potential for mitigating the progression of Parkinson's disease. About Ibogaine by David Dardashti: Ibogaine by David Dardashti is dedicated to exploring the therapeutic potential of ibogaine and promoting responsible research into its applications for addiction, neurological disorders, and overall well-being.
Associated Press
21-02-2025
- Health
- Associated Press
Ibogaine by David Dardashti Explores Groundbreaking Research Linking Genetic Enhancers to Neurological Disease Treatment, Including Parkinson's
Ibogaine by David Dardashti, a leading voice in the exploration of ibogaine's therapeutic potential, is closely analyzing a new study published in EMBO Reports that sheds light on the intricate genetic mechanisms underlying neurological disorders, including Parkinson's disease. This research, spearheaded by Associate Professor Masahito Yoshihara and colleagues, provides compelling evidence that could significantly impact the understanding and application of ibogaine treatment. The study utilized advanced genomic techniques, including CAGE, NET-CAGE, and Capture Hi-C/HiCap, to identify and characterize thousands of enhancers – non-coding DNA regions that play a crucial role in gene regulation – active during neuronal differentiation. Crucially, the researchers discovered a significant enrichment of genetic variants (SNPs) associated with Parkinson's disease and schizophrenia within these enhancers. This finding suggests that these enhancers, and the genes they regulate, are directly implicated in the development and progression of these conditions. David Dardashti, a prominent advocate for ibogaine research, recognizes the profound implications of this study for the field of ibogaine therapy. 'This research provides a critical piece of the puzzle in understanding how ibogaine may exert its remarkable effects,' Dardashti explains. 'By demonstrating the direct involvement of specific genetic enhancers in neurological disorders, it opens up exciting new avenues for exploring ibogaine's mechanism of action at a molecular level.' Ibogaine has shown promise in anecdotal reports and preliminary studies for its ability to alleviate symptoms of neurological conditions, including addiction, and potentially Parkinson's. Its purported anti-aging and restorative properties have also garnered significant interest. While the exact mechanisms remain under investigation, one hypothesis centers on ibogaine's potential to influence gene expression, possibly through interactions with these very enhancers identified in the EMBO Reports study. The study's focus on LUHMES cells, a model for human dopaminergic neurons (the cells primarily affected in Parkinson's disease), is particularly relevant. By linking specific enhancers to genes involved in neuronal differentiation and disorders, the research provides a potential roadmap for understanding how ibogaine might influence these crucial cellular processes. Dardashti is particularly intrigued by the potential connection between the identified genetic enhancers and the 'genetic rejuvenating factors' hypothesized to be influenced by ibogaine. 'If ibogaine can modulate the activity of these enhancers, which are clearly linked to neurological health and disease, it could explain its reported ability to promote neuroplasticity, reduce neuroinflammation, and potentially even reverse some of the cellular damage associated with conditions like Parkinson's,' he notes. The research highlights the 'vast regulatory potential embedded in non-coding regions' of the genome. This aligns with the emerging understanding of ibogaine's potential to induce broad-spectrum changes in gene expression, leading to long-lasting therapeutic effects. Ibogaine by David Dardashti is committed to rigorously examining the findings of this and other related studies. This deeper dive will help determine, specifically the implications for ibogaine treatment protocols and future research directions. The goal is to move beyond anecdotal evidence and establish a solid scientific foundation for ibogaine's use in treating neurological disorders, including the potential for mitigating the progression of Parkinson's disease. About Ibogaine by David Dardashti: Ibogaine by David Dardashti is dedicated to exploring the therapeutic potential of ibogaine and promoting responsible research into its applications for addiction, neurological disorders, and overall well-being. Media Contact
